GLP-1 RA – Medxy AI

Glucagon-Like Peptide-1 Receptor Agonists and Vascular Protection: Mitigating Systemic and Ocular Risks in High-Risk Type 2 Diabetes

By MedXY 04/27/2026

A large-scale cohort study demonstrates that GLP-1 RAs significantly reduce macrovascular and microvascular complications, including proliferative retinopathy and retinal vein occlusion, in patients with pre-existing diabetic retinopathy.

Cardiology Diabetes & Endocrinology news

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management

By MedXY 02/02/2026

The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduction of concomitant antihypertensive medications.

Clinical Updates Gastroenterology news

Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis

By MedXY 01/10/2026

This review synthesizes findings from the MAESTRO-NASH trial, highlighting that Resmetirom's efficacy is maintained alongside GLP-1 RAs and SGLT2 inhibitors, while being significantly enhanced by concurrent weight loss.

Clinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

GLP-1 Receptor Agonists and Risk of GERD in Type 2 Diabetes: Clinical Implications from a Large Population-Based Cohort Study

By MedXY 07/31/2025

GLP-1 receptor agonists modestly increase the risk of GERD and its complications compared to SGLT-2 inhibitors in type 2 diabetes patients, highlighting the need for vigilant symptom monitoring.